Osteosarcoma with widespread metastasis in a 1-year-old crossbred rabbit.

A 14-month-old female spayed, small crossbred rabbit presented for assessment of a small, hard subcutaneous nodule in the right axilla. Serum biochemistry showed markedly increased serum ALP activity. A whole-body CT revealed an aggressive, monostotic osteolytic, and productive lesion within the left alveolar process of the maxilla, with erosion of the alveolar bone and secondary premolar depression. Innumerable metastatic osseous masses were present throughout the body, including cerebral, pulmonary, hepatic, subcutaneous, and skeletal muscular metastases. Postmortem findings confirmed widespread, metastatic osteosarcoma, with the primary lesion within the left maxilla.

Successful intraoperative ultrasound-guided retrieval of intracranial grass seed foreign body in a 4-month-old puppy.

A 4-month-old female-entire Vizsla dog was referred for progressive seizure activity, vomiting, lethargy, inappetence, and neck pain. CT revealed focal inflammation, a calvarial osseous defect, a possible foreign body within the brain, and associated vasogenic edema. A cerebrospinal fluid tap revealed marked septic neutrophilic pleocytosis. MRI findings supported diagnosis of a 1.7 cm foreign body within the brain. A right rostrotentorial craniectomy was performed, and intraparenchymal grass seed was removed in its entirety via intraoperative ultrasound guidance. The patient was discharged 2 days postoperatively, and long-term follow-up revealed no abnormal neurological signs.

Pharmacokinetics of subcutaneously administered doramectin in alpacas.

The objective of this research was to evaluate comparative pharmacokinetics of doramectin in alpacas, after subcutaneous administration of 0.2 mg/kg dose. Six healthy adult alpacas, mean age of 5 years ± 1, (three female and three gelded males) of mean bodyweight of 62 kg ± 16 kg with an average body condition scored 2.8 ± 1 out of five, were used in this study. Serial blood samples were collected from the jugular vein before the administration until day 21 afterwards to establish the pharmacokinetics of doramectin after its subcutaneous administration at 0.2 mg/kg dose. The blood samples were analysed using high-performance liquid chromatography (HPLC), fluorescence detection method with precolumn derivatisation, validated for alpacas. The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days). The results of this study showed that the Cmax and AUC were much lower than in cattle and sheep at the same dosage. Tmax remained similar to cattle and sheep. This study presents valuable information about pharmacokinetics of doramectin in alpacas, which can be utilised in its future efficacy studies.